# Pre-emptive, OCT guided angioplasty of vulnerable, intermediate coronary lesions: a randomized trial

Published: 03-02-2016
Last updated: 19-03-2025

To determine the effect of the stenting of intermediate, vulnerable coronary lesions on the prevention of future ACS, in patients with residual non-obstructive CAD after PCI for myocardial infarction.

| | |
|---|---|
| **Ethical review** | Approved WMO |
| **Status** | Recruitment stopped |
| **Health condition type** | Coronary artery disorders |
| **Study type** | Interventional |

## Summary

### ID

NL-OMON43561

**Source**
ToetsingOnline

**Brief title**
the PECTUS trial

### Condition

- Coronary artery disorders
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis

**Synonym**
Atherosclerosis, vulnerable plaque

**Research involving**
Human

### Sponsors and support

**Primary sponsor:** Vrije Universiteit Medisch Centrum
**Source(s) of monetary or material Support:** Abbott,Abbott Vascular en St Jude

Medical,St. Jude Medical

## Intervention

**Keyword:** BVS, OCT, Stenting, Vulnerable plaque

## Outcome measures

### Primary outcome

a composite of major adverse cardiovascular events (all cause mortality,

non-fatal myocardial infarction (STEMI or NSTEMI), or unplanned

revascularization) at one year follow-up.

### Secondary outcome

The primary outcome at 2 and 5 year follow up

# Study description

### Background summary

Recently, major advances in the treatment of acute coronary syndromes have been made, but still there is a large proportion of patients at risk for new coronary events after experiencing ACS. In addition to medical treatment, detection of residual vulnerable plaques after ACS and local treatment by means of coronary intervention can further reduce adverse cardiac events in this group of unstable patients.

### Study objective

To determine the effect of the stenting of intermediate, vulnerable coronary lesions on the prevention of future ACS, in patients with residual non-obstructive CAD after PCI for myocardial infarction.

### Study design

This is a multi center, randomized clinical trial. After PCI for myocardial infarction patients with residual, hemodynamically non-obstructive plaque will be analysed for vulnerability by means of CCTA (optional) and OCT. Patients with vulnerable coronary segments on OCT wil be randomized to biovascular

scaffold (BVS) placement or medical treatment.

### Intervention

After inclusion, patients will undergo coronary CT (optional) and OCT to determine if the residual stenose is vulnerable. In case of vulnerable plaques on OCT patients will be randomized to PCI with BVS placement or to conservative (optimal medical) therapy.

### Study burden and risks

Patients included in the trial will undergo coronary CTA, unless there are logistical or clinical issues hindering the use of CTA. If CTA shows features of plaque vulnerability or if CTA is not performed, patients will undergo FFR. After FFR (if there is a hemodynamically important stenosis, patients will undergo PCI according to the guidelines), OCT will be performed to confirm plaque vulnerability. If this is the case, half of these patients will undergo PCI with BVS placement. Thus patients will be admitted to the hospital for 1-2 days and exposed to radiation (CTA and ICA), the risks of intracoronary imaging and possibly to PCI. Extra bloodsamples will be taken after informed consent and when patients are randomised to intervention extra bloodsamples will be taken after PCI. Patients will be followed by telephonic follow-up at 1, 2 and 5 years for 10 minutes. Furthermore, the first 25 randomized patients will be followed by telephonic contact after 30 days (±7 days). Risk/benefit: expected benefit is a reduction in major adverse cardiac events, at the cost of an expected low amount of procedure related complications.

## Contacts

**Public**
Vrije Universiteit Medisch Centrum

de Boelelaan 1118
Amsterdam 1081 HV
NL
**Scientific**
Vrije Universiteit Medisch Centrum

de Boelelaan 1118
Amsterdam 1081 HV
NL

# Trial sites

## Listed location countries

Netherlands

# Eligibility criteria

**Age**
Adults (18-64 years)
Elderly (65 years and older)

## Inclusion criteria

- patients with acute myocardial infarction and residual, non-obstructive CAD, with the possibility of plaque vulnerability.
- the coronary lesion must be suitable for PCI with a commercially available BVS.

## Exclusion criteria

- Refusal or inability to provide informed consent.
- < 18 years of age
- Previous CABG.
- Indication for revascularization by CABG.
- Target vessel diameter < 2,5 mm or >4.0 mm
- Anatomy or lesions unsuitable for OCT catheter crossing or imaging (aorta-ostial lesions, small diameter segment, severe calcifications)
- Anatomy unsuitable for BVS placement (left main, bifurcation stenting, sidebranch (> 2 mm) involvement).
- Target lesion is instent restenosis
- Target lesion is chronic total occlusion
- Severe kidney disease defined as an eGFR < 30 ml/min.
- Target lesion in the same vessel as the treated culprit lesion
- Target lesion in the same segment as a previously implanted stent/scaffold
- Estimated life expectancy < 1 year

# Study design

## Design

| | |
|---|---|
| Study phase: | 3 |
| Study type: | Interventional |
| Intervention model: | Parallel |
| Allocation: | Randomized controlled trial |
| Masking: | Open (masking not used) |

**Primary purpose:** Treatment

## Recruitment

NL

| | |
|---|---|
| Recruitment status: | Recruitment stopped |
| Start date (anticipated): | 04-03-2016 |
| Enrollment: | 1000 |
| Type: | Actual |

## Medical products/devices used

| | |
|---|---|
| Generic name: | Absorb GT1 stent |
| Registration: | Yes - CE intended use |

# Ethics review

| | |
|---|---|
| Approved WMO Date: | 03-02-2016 |
| Application type: | First submission |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 06-05-2016 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 19-01-2017 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |

# Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

ID: 26010
Source: Nationaal Trial Register
Title:

## In other registers

| Register | ID |
|---|---|
| CCMO | NL55011.029.15 |
| OMON | NL-OMON26010 |